236 related articles for article (PubMed ID: 32538237)
1. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC
J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237
[TBL] [Abstract][Full Text] [Related]
2. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
[TBL] [Abstract][Full Text] [Related]
3. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
[TBL] [Abstract][Full Text] [Related]
5. Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
Sorrentino A; Steinhorn B; Troncone L; Saravi SSS; Badole S; Eroglu E; Kijewski MF; Divakaran S; Di Carli M; Michel T
Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H617-H626. PubMed ID: 31298558
[TBL] [Abstract][Full Text] [Related]
6. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
[TBL] [Abstract][Full Text] [Related]
7. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Li X; Braza J; Mende U; Choudhary G; Zhang P
Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
[TBL] [Abstract][Full Text] [Related]
9. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
10. [Sacubitril/valsartan attenuates left ventricular remodeling and improve cardiac function by upregulating apelin/APJ pathway in rats with heart failure].
Liu HZ; Gao CY; Yuan F; Xu Y; Tian H; Wang SQ; Zhang PF; Shi YN; Wei JJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):690-697. PubMed ID: 35856226
[No Abstract] [Full Text] [Related]
11. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
12. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
13. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
[TBL] [Abstract][Full Text] [Related]
14. The impact of Sacubitril/Valsartan on cardiac fibrosis early after myocardial infarction in hypertensive rats.
Liu Y; Zhong C; Si J; Chen S; Kang L; Xu B
J Hypertens; 2022 Sep; 40(9):1822-1830. PubMed ID: 35943105
[TBL] [Abstract][Full Text] [Related]
15. A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload.
Maslov MY; Foianini S; Orlov MV; Januzzi JL; Lovich MA
J Card Fail; 2018 Nov; 24(11):773-782. PubMed ID: 30347271
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
[TBL] [Abstract][Full Text] [Related]
17. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.
Clements RT; Vang A; Fernandez-Nicolas A; Kue NR; Mancini TJ; Morrison AR; Mallem K; McCullough DJ; Choudhary G
Circ Heart Fail; 2019 Nov; 12(11):e005819. PubMed ID: 31707802
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction.
De Vecchis R; Paccone A; Di Maio M
Minerva Cardioangiol; 2019 Dec; 67(6):456-463. PubMed ID: 31625704
[TBL] [Abstract][Full Text] [Related]
20. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction.
Vergaro G; Del Franco A; Carecci A; Ferrari Chen YF; Aimo A; Forini F; Nicolini G; Kusmic C; Faita F; Castiglione V; De Tata V; Pucci A; Musetti V; Burchielli S; Passino C; Emdin M
Int J Cardiol; 2024 Aug; 409():132203. PubMed ID: 38795973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
